Carboplatin
Jump to navigation
Jump to search
In oncology, carboplatin is a antineoplastic agent that is an "organoplatinum compound that possesses antineoplastic activity."[1]
As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2]
Dosage
Carboplatin may be dosed by the Calvert formula:[3]
History
In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[4] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[5]
External links
The most up-to-date information about Carboplatin and other drugs can be found at the following sites.
- Carboplatin - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Carboplatin - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Carboplatin - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
- ↑ Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. (1989). "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.". J Clin Oncol 7 (11): 1748-56. PMID 2681557.
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration